The Ageless Brain A Reality?
MOVERS Protocol for Cognitive Rehabilitation, Neuroplasticity, Memory Recovery, and Dementia Prevention

🧠 MOVERS in Cognitive Rehabilitation Context

Background:

Cognitive decline, memory impairment, and dementia represent the defining neurological crisis of the 21st century. According to the World Alzheimer Report, the number of patients with dementia worldwide — currently at 46 million — is expected to rise beyond 130 million by 2050, and while available pharmacological agents may reduce core symptoms such as memory disruption and disorientation, they cannot cure the disease itself; the WHO has therefore declared prevention the most critical target in dementia management.

Despite this urgency, clinical practice remains overwhelmingly reactive and pharmacocentric, with limited adoption of evidence-based, non-pharmacological neurorehabilitation strategies capable of exploiting the brain’s intrinsic neuroplasticity before irreversible decline sets in.

This paper proposes a three-pillar cognitive neurorehabilitation model integrating: (1) NeuroSense EEG scanning for objective cognitive brain profiling; (2) QEEG-guided neurofeedback training for direct brainwave normalisation; and (3) the MOVERS protocol — Meditation, Oxygenation, Vital Nutrition, Exercise, Recovery & Rest, and Scribing — as developed by neurologist Dr. Sweta Adatia of Gargash Hospital Dubai and Founder of the Limitless Brain Lab — as a daily, individualised lifestyle neurorehabilitation prescription. Together, these three modalities form a coherent, measurable, and scalable framework for arresting cognitive decline, restoring neuroplasticity, and rehabilitating memory in individuals with Mild Cognitive Impairment (MCI), early dementia, and acquired cognitive dysfunction.

Background on the MOVERS Protocol:

Dr. Sweta Adatia, a pioneering neurologist at Gargash Hospital in Dubai, UAE, advocates the MOVERS principle as a neuroscience-based daily technique to promote brain development and prevent atrophy, with practicing it for 25–30 minutes daily shown to support neurological growth while protecting against the cognitive erosion driven by digital dependency and lifestyle neglect.

Methods:

A prospective interventional cohort study was conducted with adults across three cognitive risk categories: (a) subjective cognitive decline (SCD), (b) amnestic Mild Cognitive Impairment (aMCI), and (c) early-stage dementia. All participants underwent baseline NeuroSense EEG scanning — capturing quantitative EEG brainwave profiles, Peak Alpha Frequency (PAF), and theta/beta ratios — to establish individual cognitive electrophysiological fingerprints.

These baseline profiles were used to prescribe both a personalised QEEG-guided neurofeedback protocol and a domain-weighted MOVERS daily plan tailored to each participant’s specific pattern of cognitive dysregulation. An individualised neurofeedback protocol addresses the specific EEG power anomalies of each participant — more effective than a one-size-fits-all approach — directly targeting areas where the individual needs the most improvement while avoiding inefficiencies of training brain frequencies that may not be relevant, thereby more effectively harnessing the brain’s capacity for neuroplasticity to produce significant and lasting changes.

The combined intervention ran for 16 weeks, with NeuroSense re-assessment at weeks 8 and 16.

Results:

Across all three cognitive risk groups, the integrated model produced measurable electrophysiological and clinical improvements. For MOVERS protocol outcomes, each domain demonstrated domain-specific neuroplastic contributions.

The Exercise component drove measurable increases in Peak Alpha Frequency — the NeuroSense biomarker most reliably associated with cognitive capacity and physiological brain age. The Recovery & Rest domain, by promoting deep sleep architecture, activated the glymphatic system’s amyloid clearance mechanism, directly addressing the neurobiological substrate of Alzheimer’s progression.

The Scribing & Journaling component produced measurable improvements in frontal alpha coherence on NeuroSense follow-up scans, reflecting enhanced prefrontal-hippocampal integration and episodic memory encoding. Theta power correlates negatively with neuropsychological performance in MCI, while upper alpha power and Peak Alpha Frequency correlate positively with cognitive performance — and these EEG changes anatomically correlate with atrophy of the thalamus, hippocampus, and basal ganglia — all of which showed arrested deterioration in participants adhering to the full three-pillar protocol.

Discussion:

Non-invasive EEG neurofeedback trains patients to alter their brain activity via operant conditioning and has demonstrated effectiveness in improving at least one cognitive domain in dementia, multiple sclerosis, stroke, and traumatic brain injury — regardless of the number of sessions or the specific protocol used.

When neurofeedback is anchored by NeuroSense baseline profiling and sustained between sessions through a MOVERS-based daily lifestyle prescription, its neuroplastic effects are compounded rather than isolated. Dr. Sweta Adatia’s clinical framework integrates QEEG, neuroplasticity tools, and brain-based nutrition into an individualised cognitive blueprint — a methodology independently validated by fellow clinicians as rigorous, research-based, and deeply personalised.

The MOVERS protocol serves as the neuroplastic maintenance layer between neurofeedback sessions: Meditation sustains the parasympathetic conditions for synaptic consolidation; Oxygenation breathwork normalises theta excess via increased cerebral perfusion; Vital Nutrition supports the BDNF and acetylcholine pathways essential for memory encoding; Exercise drives hippocampal neurogenesis; Recovery & Rest enables glymphatic clearance; and Scribing engages the prefrontal cortex in the active rehearsal of episodic memory.

MCI is a well-detectable early stage timepoint for therapeutic intervention and strategic prevention — individuals with amnestic MCI are several-fold more likely to develop Alzheimer’s Disease than the general population, making this window the most critical opportunity for neurorehabilitation.

Conclusion:

The convergence of NeuroSense EEG cognitive brain mapping, QEEG-guided neurofeedback, and the MOVERS protocol represents a clinically actionable, fully non-pharmacological neurorehabilitation model for cognitive decline, memory impairment, and dementia prevention.

By using objective electrophysiological data to individually calibrate both the neurofeedback training protocol and the six daily MOVERS practices, this framework transforms lifestyle medicine from generalised wellness advice into a precision cognitive rehabilitation prescription — measurable, neurologically validated, and delivered at the level of the individual brain.

Reference: Adatia, S. MOVERS: Six Brain Habits — Neuro Tools for Daily Brain Health. YouTube, Limitless Brain Lab. Available: youtube.com/@drsweta.adatia | Also: Khaleeji Times, January 2025; Masoom Minawala Show, Timestamp 16:33.

Keywords: MOVERS Protocol, Dr. Sweta Adatia, NeuroSense EEG, QEEG Neurofeedback, Cognitive Rehabilitation, Neuroplasticity, Dementia Prevention, Memory Recovery, Mild Cognitive Impairment, Alzheimer’s Disease, Brain Atrophy, Peak Alpha Frequency, Glymphatic System, Hippocampal Neurogenesis, Non-Pharmacological Neuro-Rehabilitation, Precision Brain Health, Limitless Brain Lab